Drug Profile
SEM 007
Alternative Names: SEM-007Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Semorex
- Developer Ariel University; Semorex
- Class Antineoplastics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Prostate cancer in Israel (unspecified route) (Semorex website, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Prostate-cancer in Israel
- 03 Aug 2016 Preclinical trials in Prostate cancer in Israel (unspecified route)